NDASUBCUTANEOUSINJECTABLE
Approved
Aug 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
4/8 — Partial
SUSTOL (granisetron) by Heron Therapeutics is serotonin 3 receptor antagonists [moa]. First approved in 2016.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SUSTOL is a subcutaneous extended-release formulation of granisetron, a serotonin-3 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). The drug works by blocking serotonin receptors in the chemoreceptor trigger zone and gastrointestinal tract. Its subcutaneous delivery provides prolonged antiemetic coverage with a single injection.
$0.088BPart D
PeakAt peak lifecycle with modest Part D utilization, suggesting a stable but niche market with limited near-term expansion opportunities for commercial teams.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Safety Study of Repeat Doses of SUSTOL in Adults
Started Jul 2022
300 enrolled
Chemotherapy-Induced Nausea and Vomiting (CINV)
Bioequivalence Study in Healthy Chinese Subjects Comparing SP-01 (Granisetron Patch) Manufactured at Two Different Sites
Started Oct 2021
66 enrolled
Healthy Volunteers
Study to Assess Bioequivalence and Adhesion Properties Between Two Granisetron Transdermal Patches.
Started Jul 2021
134 enrolled
Healthy Volunteers
Granisetron Extended Release Injection (GERSC) for the Prevention of Chemotherapy-induced Nausea and Vomiting
Started Aug 2020
0Chemotherapy-induced Nausea and Vomiting
Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis
Started Jan 2019
0Gastroparesis
Worked on SUSTOL at Heron Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.